Publications - Functional Cancer Genomics Lab
Relevant publications
- Bolis M, Bossi D, Vallerga A, Ceserani V, Cavalli M, Rito Ld, Zoni E, Mosole S, Rinaldi A, Mestre RP, D'Antonio E, Ferrari M, Stoffel F, Jermini F, Sommer SG, Bubendorf L, Schraml P, Moch H, Spahn M, Thalmann G, Julio MK, Rubin M, Theurillat JP. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat Commun (2021), 12:7033.
- Canale FP, Basso C, Antonini G, Perotti M, Li N, Sokolovska A, Neumann J, James MJ, Geiger S, Jin W, Theurillat JP, West KA, Leventhal DS, Lora JM, Sallusto F and Geiger R. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature (2021) 598, 662-666.
- Bernasocchi T, El Tekle G, Bolis M, Mutti A, Vallerga A, Brandt LP, Spriano F, Svinkina T, Zoma M, Ceserani V, Rinaldi A, Janouskova H, Bossi D, Cavalli M, Mosole S, Geiger R, Dong Z, Yang CG, Albino D, Rinaldi A, Schraml P, Linder S, Carbone GM, Alimonti A, Bertoni F, Moch H, Carr SA, Zwart W, Kruithof-de Julio M, Rubin MA, Udeshi ND and Theurillat JP. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nat Commun (2021) 12, 734.
- Formaggio N, Rubin MA and Theurillat JP. Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene (2021) 40, 1205-1216.
- El Tekle G, Bernasocchi T, Unni AM, Bertoni F, Rossi D, Rubin MA and Theurillat JP. Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends Cancer (2021).
- Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, Grosjean J, Klima I, Garofoli A, Bolis M, Vallerga A, Theurillat JP, De Filippo MR, Genitsch V, Keller D, Booij TH, Stirnimann CU, Eng K, Sboner A, Ng CKY, Piscuoglio S, Gray PC, Spahn M, Rubin MA, Thalmann GN and Kruithof-de Julio M. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun (2021) 12, 1117.
- Nabais Sa MJ, El Tekle G, de Brouwer APM, Sawyer SL, Del Gaudio D, Parker MJ, Kanani F, van den Boogaard MH, van Gassen K, Van Allen MI, Wierenga K, Purcarin G, Elias ER, Begtrup A, Keller-Ramey J, Bernasocchi T, van de Wiel L, Gilissen C, Venselaar H, Pfundt R, Vissers L, Theurillat JP and de Vries BBA. De Novo Variants in SPOP Cause Two Clinically Distinct Neurodevelopmental Disorders. Am J Hum Genet (2020) 106, 405-411.
- Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ and Theurillat JP. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med (2017) 23, 1046-1054.
- Groner AC, Brown M and Theurillat JP. Targeting transcriptional co-activators in advanced prostate cancer. Cell Cycle (2016) 15, 3333-3334.
- Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild PJ, Theurillat JP and Brown M. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell (2016) 29, 846-858.
